Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?

Documents similaires

• Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
  par: C. M. Fernández‐Rodríguez, et autres
  Publié: (2024)
• Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis?
  par: John E. Eaton, et autres
  Publié: (2024)
• The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
  par: María Hernández‐Pérez, et autres
  Publié: (2024)
• Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
  par: Lukas Burghart, et autres
  Publié: (2024)
• Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
  par: Ayesha Shah, et autres
  Publié: (2024)